Lung Cancer

Only 14% of newly diagnosed lung or colorectal cancer patients reported discussing clinical trial participation with their physician, and fewer participated.

The FDA granted breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 agent for the treatment of patients with non-small-cell lung cancer who do not have EGFR mutations or ALK rearrangements.

A new study suggests that expression of the enzyme thymidylate synthase can be used as a predictive marker for lung cancer patients undergoing chemotherapy.

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

The MAGRIT trial showed no benefit with the recMAGE-A3 + AS15 cancer immunotherapeutic compared with placebo in completely resected, MAGE-A3-positive NSCLC.

Continuing gefitinib after acquiring resistance to the TKI adds no clinical benefit in patients with EGFR-positive non-small-cell lung cancer, according to trial results presented at the 2014 ESMO Congress.

Adding thoracic radiotherapy to chemotherapy and prophylactic cranial irradiation improved 2-year survival in extensive-stage small-cell lung cancer patients.

Exhaled breath temperature higher than 34 degrees Celsius (93.2 degrees F) could serve as a cutoff value to help diagnose lung cancer, according to a new study.

A new analysis of the NLST showed that both the benefits and harms of low-dose CT screening are slightly greater among patients older than 65 years.

A new study sheds light on the prevalence of ALK positive non–small-cell lung cancer and suggests the best methods for screening.

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Overall lung cancer rates have declined in the United States, but a new study shows how certain subtypes and demographic groups have more complicated trajectories.

Combining the EGFR inhibitors afatinib and cetuximab resulted in clinical responses among advanced lung cancer patients who had previously stopped responding to monotherapy treatment with other EGFR inhibitors.

Brachytherapy did not reduce rates of local recurrence after sublobar resection in patients with non–small-cell lung cancer, according to results of a new study.

A phase III trial of the insulin-like growth factor 1 receptor inhibitor figitumumab showed no benefit in survival outcomes when added to standard chemotherapy in patients with advanced non–small-cell lung cancer.

Cisplatin, etoposide, and irinotecan outperformed topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) in a Japanese trial, though there was substantially increased toxicity with the regimen.

The addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), according to results of the REVEL trial.

An 81-year-old Chinese male never-smoker with a medical history of hypertension and hyperlipidemia presented with a productive cough and a 5-lb weight loss over 3 months.

Several factors affect physicians’ choice of genomic tests, including availability, speed, and cost. Traditionally allelotyping have been used, since they are fast and sensitive, even though they are not comprehensive.

The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study presented at ASCO.

The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.

Thoracic radiotherapy along with prophylactic cranial irradiation (PCI) significantly prolonged progression-free and overall survival in patients with extensive-stage small-cell lung cancer, according to results of a new study presented at ASCO.

The addition of the MET-targeting antibody onartuzumab to erlotinib added no benefit, and may have been detrimental, to patients with MET-amplified stage IIIb/IV metastatic non–small-cell lung cancer, according to a new phase III trial.

As part of our coverage of the 2014 ASCO Annual Meeting, we discuss chemotherapy's curative role in treating lung cancer.

To ultimately find what we are actually looking for, the invasive malignant nodule in a haystack of benign lesions, new strategies and qualitative and quantitative tools are needed to propel noninvasive evaluation of solitary pulmonary nodules into the 21st century.